Lung Cancer | Specialty

Model Emerges for Targeting Oncogenes in NSCLC

December 30th 2013

Between 2007 and 2011, a collaboration among clinical oncologists, pathologists, and industry scientists led to the identification of a new molecularly defined subset of non-small cell lung cancer, followed by the finding that crizotinib, then under development as a MET inhibitor, was an inhibitor of anaplastic lymphoma kinase.

Dr. Belani Discusses Treating NSCLC with CO-1686

December 6th 2013

Chandra P. Belani, MD, discusses CO-1686, which is currently being studied for the treatment of non-small cell lung cancer.

Dr. Herbst on PD-1 Inhibitors in Lung Cancer

November 26th 2013

Roy S. Herbst, MD, PhD, discusses the sequencing possibilities of anti-PD-1 agents in treating patients with lung cancer.

Dr. Piperdi on the Stimuvax Vaccine in Lung Cancer

November 20th 2013

Bilal Piperdi, MD, from the Albert Einstein College of Medicine, discussed a trial looking at a vaccine in patients with lung cancer at the 8th Annual New York Lung Cancer Symposium®.

Dr. Mark G. Kris on the Future of Lung Cancer

November 19th 2013

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the future of lung cancer treatment at the 8th Annual New York Lung Cancer Symposium®

Individualized Treatment for Non-Small Cell Lung Cancer

November 15th 2013

Drug research and development continues to focus on regimens that select therapy according to the pathologic and molecular characteristics of the tumor.

PD-1 and PD-L1 Inhibitors Expected to 'Change the Landscape' of Lung Cancer Treatment

November 11th 2013

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

Next Generation ALK Inhibitors Poised to Become Standard of Care for Crizotinib-Resistant Patients

November 11th 2013

Next-generation ALK inhibitors are being developed to address the unmet need of patients with non-small cell lung cancer who are becoming resistant to crizotinib.

Targeted Therapies Explored in Small Cell Lung Cancer

November 11th 2013

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

Dr. Rizvi on PD-1 and PD-L1 Inhibitors in Lung Cancer

November 10th 2013

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Dr. Shaw on Monitoring Crizotinib-Related Side Effects

November 10th 2013

Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses monitoring adverse events associated with crizotinib when treating patients with ALK-positive lung cancer

NY Symposium Tackles Emerging Agents, Pressing Questions in Lung Cancer

November 8th 2013

Leaders in thoracic medical oncology from major cancer centers will come together Saturday to discuss advances in the field of lung cancer treatment during the 8th Annual New York Lung Cancer Symposium® in New York City.

Dr. Paul Bunn on TKIs in Advanced Lung Cancer

November 4th 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors

ALK-Positive Criteria for Determining Crizotinib Use May Fall Short

November 4th 2013

The criteria that are presently used to determine whether patients with non-small cell lung cancer may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug.

Dr. Gaspar on Treating Brain Metastases in Lung Cancer

October 29th 2013

Laurie Gaspar, MD, professor and chair of the Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the treatment of brain metastases in patients with lung cancer.

Nivolumab Survival Benefit Extended in Updated NSCLC Results

October 28th 2013

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013